This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Efficacy

Authoring team

Large trials of galantamine have shown clinically meaningful improvements in treated versus placebo groups:

  • four point improvement in ADAS-cog score vs placebo at 6 months
  • significant benefit from treatment at 12 months

Improvements are also seen in behaviour and activities of daily living.

Reference:

  • 1) Wilcock, GK, Lilienfeld, S, Gaens, E. (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ, 321, 1445.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.